Cardiomyocyte Proliferation
2017; Lippincott Williams & Wilkins; Volume: 120; Issue: 4 Linguagem: Inglês
10.1161/circresaha.116.310058
ISSN1524-4571
Autores Tópico(s)Tissue Engineering and Regenerative Medicine
ResumoHomeCirculation ResearchVol. 120, No. 4Cardiomyocyte Proliferation Free AccessDiscussionPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessDiscussionPDF/EPUBCardiomyocyte ProliferationTeaching an Old Dogma New Tricks Katherine E. Yutzey Katherine E. YutzeyKatherine E. Yutzey From the Heart Institute, Division of Molecular Cardiovascular Biology, Cincinnati Children's Hospital Medical Center, OH. Originally published17 Feb 2017https://doi.org/10.1161/CIRCRESAHA.116.310058Circulation Research. 2017;120:627–629The inability of the adult heart to repair or regenerate is manifested in prevalent morbidity and mortality related to myocardial infarction and heart failure. Cardiomyocyte proliferation, especially after myocardial infarction or in the context of heart failure, has been an area of intense research by many investigators for decades. As a researcher working in this area for the past 25 years, this has been an exciting time, requiring an open mind in leaving old accepted ideas behind and moving forward toward exploiting this new knowledge of cardiomyocyte plasticity.Too often, the heart does not have the capacity to overcome loss of cardiac muscle cells after injury, thus contributing to heart failure and death in the long term. For many years, the prevailing dogma was that adult mammalian cardiomyocytes are postmitotic because of irreversible cell cycle withdrawal and a switch to hypertrophic growth soon after birth. More recently, low levels of cardiomyocyte proliferation have been found in adult mammalian hearts, including humans. In addition, genetic manipulations in mice provide evidence that barriers to adult cardiomyocyte proliferation can be overcome based on knowledge of normal developmental transitions of cardiomyocyte maturation. Studies of regenerating zebrafish and neonatal mouse hearts also have identified mechanisms of cardiomyocyte dedifferentiation and proliferation with implications for promoting cardiomyocyte proliferation in adults. The accumulating evidence that resident cardiomyocytes can be stimulated to proliferate holds promise for the development of new and more effective treatments for the most devastating types of cardiovascular disease.Evolving Views of Cardiomyocyte Proliferation and RegenerationIn the 1900s, adult mammalian cardiomyocytes were viewed as postmitotic and refractory to regeneration or repair, originally based on cytology and later on electron microscopy.1 The prevailing dogma, based largely on studies in rodents, was that differentiated cardiomyocytes could proliferate in utero, but after birth, cardiomyocytes undergo 1 to 2 rounds of proliferation, become binucleated, and withdraw from the cell cycle.2 Subsequent heart growth was viewed as attributable to hypertrophy of existing cardiomyocytes in juveniles and adults with essentially no turnover or addition of new muscle cells. The adult heart was thought to respond to physiological or pathological stresses by undergoing hypertrophy, with reactivation of aspects of the fetal program, but was considered unable to generate new muscle through proliferation.In the 1990s and early 2000s, multiple studies provided evidence that adult mammalian cardiomyocytes can proliferate. However, the rate of proliferation was an area of debate in the literature and at scientific meetings. Rigorous analysis of cardiomyocyte proliferation based on 14C exposure in humans and 15N labeling in mice demonstrated low levels of cardiomyocyte proliferation in children and adults.3,4 In mice, the new myocytes arise from existing differentiated cardiomyocytes, supporting their ability to proliferate.4 Over time, the field came to accept that adult cardiomyocytes could proliferate, albeit at low frequencies ( 7 days resulted in scarring, not new muscle formation.7 Again, the new muscle generated after neonatal injury arises from differentiated cardiomyocytes, further supporting the ability of differentiated cardiomyocytes to produce new muscle cells. Although less is known of human cardiomyocyte maturation and proliferation, there is evidence that cardiomyocytes from infants have an increased capacity to proliferate and respond to regenerative signals relative to older children or adults.8 Studies in large animal models will be necessary to determine the time window of potential cardiomyocyte proliferation after birth with important clinical implications for surgical repair of congenital heart malformations in infants.Developmental Regulation of Cardiomyocyte ProliferationBefore birth, the heart is one of the few organs in which differentiated cells proliferate in the context of a functioning organ.8 During embryogenesis, mitotic figures are obvious in differentiated cardiomyocytes with sarcomeric structures, and the heart grows primarily by hyperplasia. Thus, differentiated cardiomyocytes have the ability to proliferate before birth. The proliferative rates of embryonic and fetal cardiomyocytes are distinct for diversified subpopulations of cardiomyocytes in compact and trabecular ventricular layers, atria, atrioventricular canal, and conduction system. These differential rates of cardiomyocyte proliferation are critical for morphogenesis and organogenesis of the heart before birth. Thus, unlike many other developing tissues, differentiated cardiomyocytes continue to proliferate in the context of a functioning organ throughout prenatal development.In the developing heart, cardiomyocyte proliferation is regulated by several different pathways (Figure).8 Neuregulin/ErbB/ERK signaling is the primary proliferative pathway in the embryonic heart. After midgestation, BMP signaling and IGF/PI3K pathways are required for hyperplastic growth of cardiomyocytes. Throughout development and after birth, the Hippo/Yap pathway is a critical regulator of cardiomyocyte proliferation and organ size. Early cardiomyocyte differentiation and specialization are regulated by several transcription factors, including members of Nkx, GATA, Mef2, Tbx, and HAND gene families. Notably, some of these same factors have been used in various combinations for reprogramming of iPS cells and cardiac fibroblasts into immature cardiomyocyte lineages.9 Thus, these factors not only regulate initial differentiation, but they also control specialization of cardiomyocytes, including late fetal proliferating cardiomyocytes.Download figureDownload PowerPointFigure. Regulatory mechanisms of cardiomyocyte proliferation and postn atal cell cycle arrest. Genetic activation of proliferative pathways or inhibition of arrest mechanisms can promote cardiomyocyte cell cycle activity and improve cardiac function after injury in adult mice.In the days after birth, mouse cardiomyocytes undergo 1 to 2 rounds of cell division, become binucleated, and switch to predominantly hypertrophic growth.2 At the same time, contractile protein isoforms switch from fetal to adult, metabolism switches from glycolytic to oxidative, cell cycle activators are repressed, cell cycle inhibitors are upregulated, and cardiomyocytes lose their ability to regenerate after injury.10 Cardiomyocyte proliferation is essentially undetectable 7 to 14 days after birth in rodents because they undergo a round of nuclear division without cytokinesis, leading to binucleation and cell cycle arrest.2 The mechanism of postnatal cardiomyocyte cell cycle withdrawal is not fully understood. Proproliferative signaling pathways and cell cycle proteins are decreased in the week after birth, whereas expression of cell cycle inhibitors is increased. Oxidative stress after birth has been implicated in the loss of proliferative or regenerative ability of cardiomyocytes after birth in mice.10 Interestingly, both zebrafish and mouse fetal/neonatal cardiomyocytes are in hypoxic environments, which has been linked to the ability to regenerate.Inducing Adult Cardiomyocyte Proliferation by Manipulation of Developmental FactorsManipulation of signaling molecules important for developmental regulation of cardiomyocyte proliferation, such as Yap and neuregulin pathway proteins, can overcome postnatal cell cycle arrest and promote adult cardiomyocyte proliferation.11 Inhibition of the Hippo pathway promotes adult cardiomyocyte cell cycle activity, cytoskeletal remodeling, dedifferentiation, and cardioprotection after injury.12,13 Activation of neuregulin signaling through activated ErbB2 also promotes robust cardiomyocyte proliferation and dedifferentiation in juvenile and adult mice.14 Conversely, the homeobox protein Meis1 promotes neonatal cardiomyocyte withdrawal through activation of multiple cell cycle inhibitors, and loss of Meis1 prolongs proliferation of cardiomyocytes after birth.15 Our laboratory generated mice with Tbx20 overexpression in adulthood that exhibit increased cardiomyocyte proliferation and repair after injury, characterized by induction of multiple proliferative pathways, repression of inhibitory pathways, and increased fetal characteristics.16 In the Tbx20-overexpressing mice, we saw alterations in Yap1, Akt, and BMP signaling, but we still do not understand how the multiple pathways that control cardiomyocyte proliferation intersect. It is becoming increasingly clear that postnatal induction of cardiomyocyte proliferation requires both induction of proliferative pathways and repression of cell cycle inhibitory pathways.A limitation of induction of cardiomyocyte proliferation after birth is that cardiac hypertrophy or cardiomegaly, ultimately leading to heart failure, can occur. Although manipulation of Hippo pathway proteins, cell cycle regulators, or microRNAs promotes adult cardiomyocyte cell cycling, these mice also exhibit cardiac dysfunction and failure in the long term.11 Ultimately, mice with enlarged hearts because of decreased Hippo signaling or associated microRNAs exhibit pathological hypertrophy and heart failure. In contrast, loss of Meis1 or overexpression of the developmental factor Tbx20 in adult differentiated cardiomyocytes leads to increased numbers of small proliferative cardiomyocytes, without causing hypertrophy or apparent cardiac dysfunction.15,16 Although overexpression of the activated ErbB2 oncogene leads to cardiomegaly and, ultimately, heart failure and death if unrestrained, transient induction of ErbB2 promotes limited cardiomyocyte proliferation and dedifferentiation, followed by redifferentiation, after injury.14 The success of this approach provides evidence that adult cardiomyocytes can be induced to dedifferentiate and proliferate for repair after injury and then mature into the more normal adult quiescent state for restoration of normal function in the long term. Thus, there is accumulating evidence that manipulation of cell cycle genes, inhibitors of proliferation, and secreted factors in adult mammalian hearts can promote cardiomyocyte proliferation and repair after injury. However, these pathways must be controlled for successful cardiac repair.New Prospects for Cardiac RepairGenetic manipulation of cardiomyocytes resulting in increased proliferation and repair after injury has been achieved using a variety of approaches in mice. Although transgenesis and gene targeting are not currently feasible in humans, cardiac delivery via emerging recombinant AAV (adeno-associated virus) or modified RNA (modRNA) technologies could be applied in large animals or clinical settings.17 Likewise, administration of paracrine factors via an epicardial patch might be an effective way to stimulate resident cardiomyocyte proliferation and repair after myocardial infarction. For current trials of cell-based therapies, it is tempting to speculate that secreted factors stimulate resident cardiomyocytes to proliferate. However, much is still not known about the fundamental biology of adult cardiomyocyte proliferation, especially in the context of the human heart. It is still not entirely clear whether hypertrophied binucleated cardiomyocytes can divide or whether there are primitive subpopulations that account for adult cardiomyocyte proliferative activity. Application of findings from cardiac development to the postnatal heart likely will continue to provide new insights into adult homeostasis and potential repair mechanisms in the years ahead.In the current era of cellular reprogramming, the concept of terminal differentiation has been called into question. Thus, the traditional view of irreversible cell lineage commitment during development has been modified to include new levels of cellular plasticity. The induction of fetal characteristics in adult cardiomyocytes by transcription factors or signaling pathways active in the developing heart is not as much of a leap as creating new cardiomyocytes by reprogramming of multipotential stem cells or fibroblasts. However, potential limitations include cardiomegaly or hypertrophy, as was observed in some mouse models, as well as possible arrhythmias because of the immaturity of myocyte conduction or poor coupling with existing myocardium. To be effective clinically, efforts to promote proliferation will need to include strategies to prevent unrestrained cardiac growth in the long term. Although we are far from clinical translation of our new knowledge of adult cardiomyocyte proliferation, the possibility that resident cardiomyocytes in an injured heart could be stimulated for repair is an exciting new direction to explore for both basic scientists and cardiologists.Sources of FundingThis work is supported by NIH/NHLBI R01 HL082716, and P01 HL069779, and a Cincinnati Children's Research Foundation endowed chair to K.E. Yutzey.DisclosuresNone.FootnotesThe opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.Correspondence to Katherine E. Yutzey, PhD, Division of Molecular Cardiovascular Biology, Cincinnati Children's Medical Center ML7020, 240 Albert Sabin Way, Cincinnati, OH 45229. E-mail [email protected]References1. Rumyantsev PP.Interrelations of the proliferation and differentiation processes during cardiact myogenesis and regeneration.Int Rev Cytol. 1977; 51:186–273.MedlineGoogle Scholar2. Soonpaa MH, Kim KK, Pajak L, Franklin M, Field LJ.Cardiomyocyte DNA synthesis and binucleation during murine development.Am J Physiol. 1996; 271:H2183–H2189.MedlineGoogle Scholar3. Bergmann O, Bhardwaj RD, Bernard S, Zdunek S, Barnabé-Heider F, Walsh S, Zupicich J, Alkass K, Buchholz BA, Druid H, Jovinge S, Frisén J.Evidence for cardiomyocyte renewal in humans.Science. 2009; 324:98–102. doi: 10.1126/science.1164680.CrossrefMedlineGoogle Scholar4. Senyo SE, Steinhauser ML, Pizzimenti CL, Yang VK, Cai L, Wang M, Wu TD, Guerquin-Kern JL, Lechene CP, Lee RT.Mammalian heart renewal by pre-existing cardiomyocytes.Nature. 2013; 493:433–436. doi: 10.1038/nature11682.CrossrefMedlineGoogle Scholar5. Poss KD, Wilson LG, Keating MT.Heart regeneration in zebrafish.Science. 2002; 298:2188–2190. doi: 10.1126/science.1077857.CrossrefMedlineGoogle Scholar6. Kikuchi K, Holdway JE, Werdich AA, Anderson RM, Fang Y, Egnaczyk GF, Evans T, Macrae CA, Stainier DY, Poss KD.Primary contribution to zebrafish heart regeneration by gata4(+) cardiomyocytes.Nature. 2010; 464:601–605. doi: 10.1038/nature08804.CrossrefMedlineGoogle Scholar7. Porrello ER, Mahmoud AI, Simpson E, Hill JA, Richardson JA, Olson EN, Sadek HA.Transient regenerative potential of the neonatal mouse heart.Science. 2011; 331:1078–1080. doi: 10.1126/science.1200708.CrossrefMedlineGoogle Scholar8. Foglia MJ, Poss KD.Building and re-building the heart by cardiomyocyte proliferation.Development. 2016; 143:729–740. doi: 10.1242/dev.132910.CrossrefMedlineGoogle Scholar9. Xin M, Olson EN, Bassel-Duby R.Mending broken hearts: cardiac development as a basis for adult heart regeneration and repair.Nat Rev Mol Cell Biol. 2013; 14:529–541. doi: 10.1038/nrm3619.CrossrefMedlineGoogle Scholar10. Puente BN, Kimura W, Muralidhar SA, et al. The oxygen-rich postnatal environment induces cardiomyocyte cell-cycle arrest through DNA damage response.Cell. 2014; 157:565–579. doi: 10.1016/j.cell.2014.03.032.CrossrefMedlineGoogle Scholar11. Uygur A, Lee RT.Mechanisms of cardiac regeneration.Dev Cell. 2016; 36:362–374. doi: 10.1016/j.devcel.2016.01.018.CrossrefMedlineGoogle Scholar12. Xin M, Kim Y, Sutherland LB, Murakami M, Qi X, McAnally J, Porrello ER, Mahmoud AI, Tan W, Shelton JM, Richardson JA, Sadek HA, Bassel-Duby R, Olson EN.Hippo pathway effector Yap promotes cardiac regeneration.Proc Natl Acad Sci USA. 2013; 110:13839–13844. doi: 10.1073/pnas.1313192110.CrossrefMedlineGoogle Scholar13. Heallen T, Morikawa Y, Leach J, Tao G, Willerson JT, Johnson RL, Martin JF.Hippo signaling impedes adult heart regeneration.Development. 2013; 140:4683–4690. doi: 10.1242/dev.102798.CrossrefMedlineGoogle Scholar14. D'Uva G, Aharonov A, Lauriola M, et al. ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation.Nat Cell Biol. 2015; 17:627–638. doi: 10.1038/ncb3149.CrossrefMedlineGoogle Scholar15. Mahmoud AI, Kocabas F, Muralidhar SA, Kimura W, Koura AS, Thet S, Porrello ER, Sadek HA.Meis1 regulates postnatal cardiomyocyte cell cycle arrest.Nature. 2013; 497:249–253. doi: 10.1038/nature12054.CrossrefMedlineGoogle Scholar16. Xiang FL, Guo M, Yutzey KE.Overexpression of Tbx20 in adult cardiomyocytes promotes proliferation and improves cardiac function after myocardial infarction.Circulation. 2016; 133:1081–1092. doi: 10.1161/CIRCULATIONAHA.115.019357.LinkGoogle Scholar17. Lin Z, Pu WT.Strategies for cardiac regeneration and repair.Sci Transl Med. 2014; 6:239rv1. doi: 10.1126/scitranslmed.3006681.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Mahiny-Shahmohammady D, Hauck L and Billia F (2022) Defining the molecular underpinnings controlling cardiomyocyte proliferation, Clinical Science, 10.1042/CS20211180, 136:12, (911-934), Online publication date: 30-Jun-2022. Najjari A, Mehdinavaz Aghdam R, Ebrahimi S, Suresh K S, Krishnan S, Shanthi C and Ramalingam M (2022) Smart piezoelectric biomaterials for tissue engineering and regenerative medicine: a review, Biomedical Engineering / Biomedizinische Technik, 10.1515/bmt-2021-0265, 67:2, (71-88), Online publication date: 26-Apr-2022., Online publication date: 1-Apr-2022. Mehdizadeh M, Aguilar M, Thorin E, Ferbeyre G and Nattel S (2021) The role of cellular senescence in cardiac disease: basic biology and clinical relevance, Nature Reviews Cardiology, 10.1038/s41569-021-00624-2, 19:4, (250-264), Online publication date: 1-Apr-2022. Dunham C, Mackenzie M, Nakano H, Kim A, Juda M, Nakano A, Stieg A, Gimzewski J and Bao X (2022) Pacemaker translocations and power laws in 2D stem cell-derived cardiomyocyte cultures, PLOS ONE, 10.1371/journal.pone.0263976, 17:3, (e0263976) Sudi S, Chin Y, Wasli N, Fong S, Shimmi S, How S and Sunggip C (2022) Carpaine Promotes Proliferation and Repair of H9c2 Cardiomyocytes after Oxidative Insults, Pharmaceuticals, 10.3390/ph15020230, 15:2, (230) Walker C, Schroeder M, Aguado B, Anseth K and Leinwand L (2021) Matters of the heart: Cellular sex differences, Journal of Molecular and Cellular Cardiology, 10.1016/j.yjmcc.2021.04.010, 160, (42-55), Online publication date: 1-Nov-2021. Rehmani T, Mlynarova J, Byers J, Salih M and Tuana B (2021) Specific Deletion of the FHA Domain Containing SLMAP3 Isoform in Postnatal Myocardium Has No Impact on Structure or Function, Cardiogenetics, 10.3390/cardiogenetics11040018, 11:4, (164-184) De Majo F, Martens L, Hegenbarth J, Rühle F, Hamczyk M, Nevado R, Andrés V, Hilbold E, Bär C, Thum T, de Boer M, Duncker D, Schroen B, Armand A, Stoll M and De Windt L (2021) Genomic instability in the naturally and prematurely aged myocardium, Proceedings of the National Academy of Sciences, 10.1073/pnas.2022974118, 118:36, Online publication date: 7-Sep-2021. Ghazal N, Peoples J, Mohiuddin T and Kwong J (2021) Mitochondrial functional resilience after TFAM ablation in the adult heart, American Journal of Physiology-Cell Physiology, 10.1152/ajpcell.00508.2020, 320:6, (C929-C942), Online publication date: 1-Jun-2021. Li Y, Chen X, Jin R, Chen L, Dang M, Cao H, Dong Y, Cai B, Bai G, Gooding J, Liu S, Zou D, Zhang Z and Yang C (2021) Injectable hydrogel with MSNs/microRNA-21-5p delivery enables both immunomodification and enhanced angiogenesis for myocardial infarction therapy in pigs, Science Advances, 10.1126/sciadv.abd6740, 7:9, Online publication date: 26-Feb-2021. Urdeitx P and Doweidar M (2021) Enhanced Piezoelectric Fibered Extracellular Matrix to Promote Cardiomyocyte Maturation and Tissue Formation: A 3D Computational Model, Biology, 10.3390/biology10020135, 10:2, (135) Ozcebe S, Bahcecioglu G, Yue X and Zorlutuna P (2021) Effect of cellular and ECM aging on human iPSC-derived cardiomyocyte performance, maturity and senescence, Biomaterials, 10.1016/j.biomaterials.2020.120554, 268, (120554), Online publication date: 1-Jan-2021. Dye B and Lincoln J (2020) The Endocardium and Heart Valves, Cold Spring Harbor Perspectives in Biology, 10.1101/cshperspect.a036723, 12:12, (a036723), Online publication date: 1-Dec-2020. Zhen L, Zhao Q, Lü J, Deng S, Xu Z, Zhang L, Zhang Y, Fan H, Chen X, Liu Z, Gu Y and Yu Z (2020) miR-301a-PTEN-AKT Signaling Induces Cardiomyocyte Proliferation and Promotes Cardiac Repair Post-MI, Molecular Therapy - Nucleic Acids, 10.1016/j.omtn.2020.08.033, 22, (251-262), Online publication date: 1-Dec-2020. Schmid C, Wohnhaas C, Hildebrandt T, Baum P and Rast G (2020) Characterization of iCell cardiomyocytes using single-cell RNA-sequencing methods, Journal of Pharmacological and Toxicological Methods, 10.1016/j.vascn.2020.106915, 106, (106915), Online publication date: 1-Nov-2020. Urdeitx P and Doweidar M (2020) A Computational Model for Cardiomyocytes Mechano-Electric Stimulation to Enhance Cardiac Tissue Regeneration, Mathematics, 10.3390/math8111875, 8:11, (1875) Hume R and Chong J (2020) The Cardiac Injury Immune Response as a Target for Regenerative and Cellular Therapies, Clinical Therapeutics, 10.1016/j.clinthera.2020.09.006, 42:10, (1923-1943), Online publication date: 1-Oct-2020. Urdeitx P and Doweidar M (2020) Mechanical stimulation of cell microenvironment for cardiac muscle tissue regeneration: a 3D in-silico model, Computational Mechanics, 10.1007/s00466-020-01882-6, 66:4, (1003-1023), Online publication date: 1-Oct-2020. Jaźwińska A and Blanchoud S (2020) Towards deciphering variations of heart regeneration in fish, Current Opinion in Physiology, 10.1016/j.cophys.2019.11.007, 14, (21-26), Online publication date: 1-Apr-2020. Gao L, Ma L, Yin X, Luo Y, Yang H and Zhang B (2020) Nano‐ and Microfabrication for Engineering Native‐Like Muscle Tissues, Small Methods, 10.1002/smtd.201900669, 4:3, (1900669), Online publication date: 1-Mar-2020. Nakamura Y, Takeba Y, Kobayashi T, Ootaki M, Ohta Y, Kida K, Sakurai K, Gen K, Watanabe M, Iiri T and Matsumoto N (2020) Yap Contributes to Cardiomyocyte Proliferation in the Fetal Rat Heart Epicardium with Antenatal Glucocorticoid Administration, Journal of St. Marianna University, 10.17264/stmarieng.11.109, 11:2, (109-122), . van der Ven C, Hogewoning B, van Mil A and Sluijter J (2020) Non-coding RNAs in Cardiac Regeneration Non-coding RNAs in Cardiovascular Diseases, 10.1007/978-981-15-1671-9_9, (163-180), . Mourouzis I (2020) The Role of Thyroid Hormone Receptor α1 in Cardiac Repair Thyroid and Heart, 10.1007/978-3-030-36871-5_13, (163-170), . Judd J, Lovas J and Huang G (2019) Defined factors to reactivate cell cycle activity in adult mouse cardiomyocytes, Scientific Reports, 10.1038/s41598-019-55027-8, 9:1, Online publication date: 1-Dec-2019. Zlabinger K, Spannbauer A, Traxler D, Gugerell A, Lukovic D, Winkler J, Mester-Tonczar J, Podesser B and Gyöngyösi M (2019) MiR-21, MiR-29a, GATA4, and MEF2c Expression Changes in Endothelin-1 and Angiotensin II Cardiac Hypertrophy Stimulated Isl-1+Sca-1+c-kit+ Porcine Cardiac Progenitor Cells In Vitro, Cells, 10.3390/cells8111416, 8:11, (1416) Elmadani M, Khan S, Tenhunen O, Magga J, Aittokallio T, Wennerberg K and Kerkelä R (2019) Novel Screening Method Identifies PI3Kα, mTOR, and IGF1R as Key Kinases Regulating Cardiomyocyte Survival, Journal of the American Heart Association, 8:21, Online publication date: 5-Nov-2019. Velayutham N, Agnew E and Yutzey K (2019) Postnatal Cardiac Development and Regenerative Potential in Large Mammals, Pediatric Cardiology, 10.1007/s00246-019-02163-7, 40:7, (1345-1358), Online publication date: 1-Oct-2019. Broughton K and Sussman M (2019) Adult Cardiomyocyte Cell Cycle Detour: Off-ramp to Quiescent Destinations, Trends in Endocrinology & Metabolism, 10.1016/j.tem.2019.05.006, 30:8, (557-567), Online publication date: 1-Aug-2019. Khan K, Makhoul G, Yu B, Schwertani A and Cecere R (2019) The cytoprotective impact of yes-associated protein 1 after ischemia-reperfusion injury in AC16 human cardiomyocytes, Experimental Biology and Medicine, 10.1177/1535370219851243, 244:10, (802-812), Online publication date: 1-Jul-2019. Borden A, Kurian J, Nickoloff E, Yang Y, Troupes C, Ibetti J, Lucchese A, Gao E, Mohsin S, Koch W, Houser S, Kishore R and Khan M (2019) Transient Introduction of miR-294 in the Heart Promotes Cardiomyocyte Cell Cycle Reentry After Injury, Circulation Research, 125:1, (14-25), Online publication date: 21-Jun-2019. Agnew E, Garcia-Burgos A, Richardson R, Manos H, Thomson A, Sooy K, Just G, Homer N, Moran C, Brunton P, Gray G and Chapman K Antenatal dexamethasone treatment transiently alters diastolic function in the mouse fetal heart, Journal of Endocrinology, 10.1530/JOE-18-0666, 241:3, (279-292) Alvarez R, Wang B, Quijada P, Avitabile D, Ho T, Shaitrit M, Chavarria M, Firouzi F, Ebeid D, Monsanto M, Navarrete N, Moshref M, Siddiqi S, Broughton K, Bailey B, Gude N and Sussman M (2019) Cardiomyocyte cell cycle dynamics and proliferation revealed through cardiac-specific transgenesis of fluorescent ubiquitinated cell cycle indicator (FUCCI), Journal of Molecular and Cellular Cardiology, 10.1016/j.yjmcc.2018.12.007, 127, (154-164), Online publication date: 1-Feb-2019. Arumugam R, Srinadhu E, Subramanian B and Nallani S (2019) β-PVDF based electrospun nanofibers – A promising material for developing cardiac patches, Medical Hypotheses, 10.1016/j.mehy.2018.10.005, 122, (31-34), Online publication date: 1-Jan-2019. Bahramian A, Mirzaei B, Karimzadeh F, Ramhmaninia F, Gaeini A, Naderi N and Hemmatinafar M (2018) The Effects of Exercise Training Intensity on the Expression of C/EBPβ and CITED4 in Rats with Myocardial Infarction, Asian Journal of Sports Medicine, 10.5812/asjsm.59300, 9:4 Dutta P and Lincoln J (2018) Calcific Aortic Valve Disease: a Developmental Biology Perspective, Current Cardiology Reports, 10.1007/s11886-018-0968-9, 20:4, Online publication date: 1-Apr-2018. Yang Q and Long Q (2018) PPARδ, a Potential Therapeutic Target for Heart Disease, Nuclear Receptor Research, 10.32527/2018/101375, 5, . Tao L, Bei Y, Li Y and Xiao J (2018) Neonatal Rat Cardiomyocytes Isolation, Culture, and Determination of MicroRNAs' Effects in Proliferation MicroRNA Protocols, 10.1007/978-1-4939-7601-0_17, (203-213), . February 17, 2017Vol 120, Issue 4 Advertisement Article InformationMetrics © 2017 American Heart Association, Inc.https://doi.org/10.1161/CIRCRESAHA.116.310058PMID: 28209795 Originally publishedFebruary 17, 2017 Keywordsadultanimaldevelopmental biologyheart failureregenerationPDF download Advertisement SubjectsCongenital Heart DiseaseHeart Failure
Referência(s)